The IGNITE-TX Study, a trial aimed at advancing genetic testing for Hereditary Breast and Ovarian Cancer (HBOC) syndrome and Lynch syndrome (LS), holds promise in addressing a significant concern highlighted by the National Comprehensive Cancer Network (NCCN). The NCCN advises that all at-risk relatives of individuals with these syndromes should undergo genetic counseling and consider cascade genetic testing. However, the current uptake of cascade genetic testing among relatives stands at fewer than 50%, indicating an opportunity to improve these rates within the patient population through this study.

Scroll down

Being aware of our genetic risks empowers us to make informed decisions


Understanding our genetic risks not only helps us make informed healthcare decisions for ourselves but also benefits our relatives. Participants in this study will provide basic information to determine eligibility. Any uncertainties regarding genetic test results or inquiries about the study will be addressed by our dedicated support team, available at every step.


Our objectives

The primary objectives of the IGNITE-TX Study include aiding families in understanding their cancer risk linked to HBOC and LS, sharing genetic testing results, and facilitating access to essential information and resources for those considering genetic testing. It’s crucial to note that both syndromes increase the likelihood of cancer occurrence in both men and women. This trial presents a unique opportunity to enhance genetic testing.

See our FAQs

Contact Us IgniteTX

Contact Us

If you have questions about the study or want more information, you can contact the study team via phone 713-792-9155 or email ignitestudy@mdanderson.org

IgniteTX Brand